[1]
S. . Kittikasemsook, P. . Torvorapanit, and C. . Nakaranurack, “Treatment outcomes and factors associated with treatment failure among patients with mild-to-moderate COVID-19 receiving five-days of oral molnupiravir vs. three-days of intravenous remdesivir in a real-world practice”, Chula Med J, vol. 70, no. 1, Jan. 2026.